Across TCGA pan-cancer cohorts, TRAV9-2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRAV9-2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TRAV9-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV9-2 expression acts as an unfavorable survival marker.

LUSC are the cancer types where TRAV9-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.326	0.728	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: TRAV9-2 tumor-vs-normal RNA expression · all TRAV9-2 data types